The Role of Glucagon-like Peptide 1 Receptor Modulators for the Management of Dumping Syndrome in Patients Who have Undergone Metabolic and Bariatric Surgery: a Scoping Review
Abstract
BACKGROUND: Dumping syndrome is a common complication following metabolic and bariatric surgery (MBS) and is associated with significant morbidity and impaired quality of life. While glucagon-like peptide-1 receptor modulators (GLP-1 RMs) are established therapies for obesity, their role in the management of dumping syndrome remains unclear. Existing literature is limited and has largely focused on postprandial hypoglycaemia as a surrogate for late dumping syndrome. OBJECTIVE: To map the current evidence regarding the safety and efficacy of GLP-1 RMs in the management of dumping syndrome following MBS, recognising dumping syndrome as a broader clinical entity encompassing symptoms, quality of life, and glucose stabilisation. METHODS: A scoping review was conducted in accordance with Joanna Briggs Institute methodology and reported using PRISMA-ScR guidelines. A comprehensive search of multiple databases was performed to identify peer-reviewed clinical studies evaluating GLP-1 RMs for dumping syndrome after MBS. Data were extracted on study design, patient characteristics, type of dumping syndrome, GLP-1 RM regimen, and clinical outcomes. RESULTS: Fifteen studies involving 107 patients were included - predominantly case reports and case series. GLP-1 receptor agonist therapy was associated in these cases with reduction or resolution of hypoglycaemic episodes and improvement in dumping-related symptoms. Limited evidence also suggested improvements in quality of life. The GLP-1…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.